Randomised clinical trial: A novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate-to-severe erosive oesophagitis - The results of two double-blind studies

Alimentary Pharmacology and Therapeutics

Volumn 33, Issue 2, 2011, Pages 203-212

  Laine, L ^a   Katz, P O ^b   Johnson, D A ^c   Ibegbu, I ^d   Goldstein, M J ^e   Chou, C ^f   Rossiter, G ^f   Lu, Y ^f  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b ALBERT EINSTEIN MEDICAL CENTER   (United States)

^c EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^d Atlantic Medical Group   (United States)

^e Long Island Clinical Research Associates   (United States)

^f EISAI INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; RABEPRAZOLE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTENDED DRUG FORMULATION; FEMALE; GASTRIN BLOOD LEVEL; HEALING; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; SIDE EFFECT; TREATMENT DURATION;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ADULT; AGED; DOUBLE-BLIND METHOD; ESOPHAGITIS; FEMALE; HEARTBURN; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PROTON PUMP INHIBITORS; SEVERITY OF ILLNESS INDEX; STATISTICS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78650283679     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04516.x     Document Type: Article

References (33)

1. Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther 2000; 14: 1249-58.
2. Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001; 96: 656-65.
3. Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002; 97: 575-83.
4. Labenz J, Armstrong D, Lauritsen K, et al. A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. Aliment Pharmacol Ther 2005; 21: 739-46.
5. Nexium (esomeprazole magnesium) delayed release capsules approval package, NDA Application No.: 21-153 & 21-154. Available at:.
6. Fennerty MB, Johanson JF, Hwang C, Sostek M,. Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis. Aliment Pharmacol Ther 2005; 21: 455-63.
7. Katz PO, Ginsberg GG, Hoyle PE, Sostek MB, Monyak JT, Silberg DG,. Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive esophagitis. Aliment Pharmacol Ther 2007; 25: 617-28.
8. Sharma P, Shaheen NJ, Perez MC, et al. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation-results from two randomized controlled studies. Aliment Pharmacol Ther 2008; 29: 731-41.
9. Holloway RH, Dent J, Narielvala F,. Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis. Gut 1996; 38: 649-54.
10. Hunt RH,. Importance of pH control in the management of GERD. Arch Intern Med 1999; 159: 649-57.
11. Armstrong D,. Review article: gastric pH- the most relevant predictor of benefit in reflux disease. Aliment Pharmacol Ther 2004; 20 (Suppl. 5): 19-26.
12. Katz PO, Johnson DA, Levine D, et al. A model of healing of Los Angeles grades C and D reflux oesophagitis: is there an optimal time of acid suppression for maximal healing? Aliment Pharmacol Ther 2010; 32: 443-7.
13. Morelli G, Chen H, Kao R, Lu Y,. Comparison of 24-hour intragastric pH following once-daily treatment with esomeprazole, rabeprazole delayed release, and six rabeprazole extended-release formulations. Gastroenterology 2010; 138 (Suppl. 1): S-648.
14. Armstrong D, Bennett JR, Blum AL, et al. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology 1996; 111: 85-92.
15. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45: 172-80.
16. Pandolfino JE, Vakil NB, Kahrilas PJ,. Comparison of inter- and intraobserver consistency for grading of esophagitis by expert and trainee endoscopists. Gastrointest Endosc 2002; 56: 639-43.
17. Rath HC, Timmer A, Kunkel C, et al. Comparison of interobserver agreement for different scoring systems for reflux esophagitis: impact of level of experience. Gastrointest Endosc 2004; 60: 44-9.
18. Bytzer P,. Assessment of reflux symptom severity: methodological options and their attributes. Gut 2004; 53 (Suppl. 4): iv28-34.
19. Stanghellini V, Armstrong D, Mönnikes H, Bardhan KD,. Systematic review: do we need a new gastro-oesophageal reflux disease questionnaire? Aliment Pharmacol Ther 2004; 19: 463-79.
20. Food and Drug Administration (FDA). Guidance for Industry: non-inferiority clinical trials draft guidance. Available at:.
21. Committee for Proprietary Medicinal Products (CPMP). Points to consider on switching between superiority and non-Inferiority. Available at:.
22. Hung J, Wang S-J, Tsong Y, Lawrence J, O'Neil RT,. Some fundamental issues with non-inferiority testing in active controlled trials. Stat Med 2003; 22: 213-25.
23. Hedges LV, Vevea JL,. Fixed and random effects models in meta analysis. Psychol Methods 1998; 3: 486-504.
24. TAP Pharmaceutical Product Inc. Prescribing Information for Prevacid® (Lansoprazole). Lake Forest, IL: TAP Pharmaceutical Product Inc, 2006.
25. AstraZeneca. Prescribing Information for Prilosec® (Omeprazole). Wilmington, DE: AstraZeneca, 2001.
26. Wyeth Laboratories. Prescribing Information for Prontonix® (Pantoprazole Sodium). Philadelphia, PA: Wyeth Laboratories, 2004.
27. Eisai Inc. Prescribing Information for Aciphex® (Rabeprazole). Woodcliff Lake, NJ: Eisai Inc, 2007.
28. Gisbert JP, Abraira V,. Accuracy of Helicobacter pylori diagnostic tests in patients with bleeding peptic ulcer: a systematic review and meta-analysis. Am J Gastroenterol 2006; 101: 848-63.
29. 13C-urea to diagnose Helicobacter pylori infection: a randomised controlled trial. Gut 2006; 55: 457-62.
30. 13C-urea breath test: reproducibility and association with the severity of Helicobacter pylori-associated antral gastritis. J Gastroenterol Hepatol 2005; 20: 270-4.
31. Delaney B, McColl K,. Review article: Helicobacter pylori and gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2005; 22 (Suppl. s1): 32-40.
32. McColl KE, El-Omar E, Gillen D,. Interactions between H. pylori infection, gastric acid secretion and anti-secretory therapy. Br Med Bull 1998; 54: 121-38.
33. Takeda Pharmaceuticals America. Prescribing Information for Dexlant® (Dexlansoprazole). Deerfield, IL: Takeda Pharmaceuticals America, Inc, 2010.